Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186812 | 0.79 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5742936 | 0.79 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5740500 | 0.79 | CTSS (0.61) | CTSSCTSKCTSLCTSB | |
| SCHEMBL14370806 | 0.76 | ALDH1A1 (0.46) | ALDH1A1AKR1C3AKR1C1KMT2ASMN1; SMN2 | |
| SCHEMBL14065364 | 0.72 | ALDH1A1 (0.53) | CTSSCTSKALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL15268630 | 0.71 | CTSS (0.48) | CTSSCTSKALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL14574455 | 0.70 | ALDH1A1 (0.38) | CTSSCTSKALDH1A1KMT2ATSHR | |
| SCHEMBL1992449 | 0.69 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1992447 | 0.69 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1995124 | 0.69 | CTSK (0.56) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-3008069-B1 | PREPARATION OF TERT-BUTYL 4-((1R,2S,5R)-6- (BENZYLOXY)-7-0X0-1,6-DIAZABICYCL0[3.2.I]OCTANE-2- CARBOXAMIDO)PIPERIDINE-1-CARBOXYLATE | MERCK SHARP & DOHME (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9604985-B2 | Process for the preparation of chiral tert-butyl 4-((1R,2S,5R)-6(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carb derivatives and (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160122350-A1 | PROCESS FOR THE PREPARATION OF CHIRAL TERT-BUTYL 4-((1R,2S,5R)-6-(BENZYLOXY)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDO)PIPERIDINE-1-CARBOXYLATE DERIVATIVES AND (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | MERCK SHARP & DOHME CORP. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-1997495-B1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2435037-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138338-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0328529-A4 | BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE | — | 1991-03-20 | — | — | EP | disclosed |
| US-4954637-A | Certain maleimide-N-alkylenecarboxylate-ortho-nitrobenzenesulfonic acid esters and derivatives useful for coupling biological materials | CETUS CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4943636-A | PROTEINS AND PEPTIDES | CETUS CORPORATION (US) | 1990-07-24 | — | — | US | disclosed |
| EP-0367393-A2 | New heterocyclic compounds, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
| EP-0196174-B1 | MEANS FOR SEQUENTIAL SOLID PHASE ORGANIC SYNTHESIS AND METHODS USING THE SAME | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0328529-A1 | METHOD FOR PREPARING POLYSUBSTITUTED DIETHYLENETRIAMINEPENTAACETIC ACIDS. | GANSOW OTTO A (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4831175-A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-05-16 | — | — | US | disclosed |
| WO-1988001618-A1 | BACKBONE POLYSUBSTITUTED CHELATES FOR FORMING A METAL CHELATE-PROTEIN CONJUGATE | GANSOW OTTO A (US) | 1988-03-10 | — | — | WO | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005176-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | CTSS 215/4885CTSK 854/4885ALDH1A1 3837/4885 |
| US-20160122350-A1 | PROCESS FOR THE PREPARATION OF CHIRAL TERT-BUTYL 4-((1R,2S,5R)-6-(BENZYLOXY)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDO)PIPERIDINE-1-CARBOXYLATE DERIVATIVES AND (2S,5R)-7-OXO-N-PIPERIDIN-4-YL-6-(SULFOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE | CYP2W1, PGLS, GPKOW | CTSS 1023/4885CTSK 1717/4885ALDH1A1 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.